Malika Ammam received her MS degree from the University of Pierre et Marie CURIE in July 2002 and her PhD from the University of Paris Sud XI, France in September 2005. From 2006 to 2007, she worked as a research fellow at the University of Kansas in collaboration with Pinnacle Technology Inc. (USA). From 2007 to 2010, she was a research associate at KU Leuven, Belgium. From 2010 to 2012, she worked at the University of Ontario Institute of Technology in collaboration with Alcohol Countermeasure Systems Corporation, Canada. She held a prestigious Rosalind Franklin fellowship and resigned in 2015. Now, she is a freelancer.
Surface Oncology recently announced promising outcomes of its immunotherapy agent SRF231, a human CD47 antibody, in clearance of tumor cells both alone and when combined with other cancer drugs. SRF231 also demonstrated ... Read more
Cyclacel Pharmaceuticals disclosed promising preclinical results of its drug candidate, CYC065, for the treatment of B-cell lymphoma in a poster presentation at the recent American Association for Cancer Research (AACR) annual meeting ... Read more
Researchers at the University of California Los Angeles (UCLA) reported that anti-inflammatory, “good” intestinal bacteria, bolstered by probiotics, may reduce the risk of developing some types of cancer, including lymphoma. Their article, ... Read more
In a recent study published in Nature Medicine, entitled “The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development“, researchers revealed the mechanisms by which mutations in the ... Read more
A recent report written by John Sweetenham, MD, in HemOnc Today, revealed that progress is being made concerning the endpoints of clinical priority studies of follicular lymphoma (FL), which has improved overall survival rate of patients ... Read more